Trials / Completed
CompletedNCT03844074
A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
A Clinical Effectiveness, Multicenter, Randomized, Double-masked, Controlled Study of the Efficacy and Safety of ONS-5010 in Subjects With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 61 (actual)
- Sponsor
- Outlook Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
This research study will examine the safety and effectiveness of ONS-5010 in participants with AMD. The goal is to prevent vision loss by evaluating the effectiveness of ONS-5010 as compared with ranibizumab.
Conditions
- Age-related Macular Degeneration
- Neovascular Age-related Macular Degeneration
- Wet Macular Degeneration
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | bevacizumab | 1.25 mg, intravitreal injection |
| BIOLOGICAL | ranibizumab | 0.5mg, intravitreal injection |
Timeline
- Start date
- 2018-10-01
- Primary completion
- 2020-07-23
- Completion
- 2020-08-13
- First posted
- 2019-02-18
- Last updated
- 2025-03-19
Locations
9 sites across 1 country: Australia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03844074. Inclusion in this directory is not an endorsement.